ATE464390T1 - Verfahren zur herstellung von insulinverbindungen - Google Patents

Verfahren zur herstellung von insulinverbindungen

Info

Publication number
ATE464390T1
ATE464390T1 AT02779247T AT02779247T ATE464390T1 AT E464390 T1 ATE464390 T1 AT E464390T1 AT 02779247 T AT02779247 T AT 02779247T AT 02779247 T AT02779247 T AT 02779247T AT E464390 T1 ATE464390 T1 AT E464390T1
Authority
AT
Austria
Prior art keywords
insulin compounds
producing insulin
compounds
insulin
ester
Prior art date
Application number
AT02779247T
Other languages
English (en)
Inventor
Are Bogsnes
Ingun Christiansen
Per Balschmidt
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE464390T1 publication Critical patent/ATE464390T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02779247T 2001-11-19 2002-11-15 Verfahren zur herstellung von insulinverbindungen ATE464390T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101716 2001-11-19
PCT/DK2002/000765 WO2003044210A2 (en) 2001-11-19 2002-11-15 Process for preparing insulin compounds

Publications (1)

Publication Number Publication Date
ATE464390T1 true ATE464390T1 (de) 2010-04-15

Family

ID=8160841

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02779247T ATE464390T1 (de) 2001-11-19 2002-11-15 Verfahren zur herstellung von insulinverbindungen

Country Status (15)

Country Link
EP (1) EP1448786B1 (de)
JP (1) JP4404631B2 (de)
KR (1) KR100925381B1 (de)
CN (1) CN100424179C (de)
AT (1) ATE464390T1 (de)
AU (1) AU2002342597A1 (de)
BR (1) BR0213583A (de)
CA (1) CA2464616C (de)
DE (1) DE60236014D1 (de)
ES (1) ES2344448T3 (de)
HU (1) HU228934B1 (de)
IL (2) IL161358A0 (de)
PL (1) PL210437B1 (de)
RU (1) RU2376379C2 (de)
WO (1) WO2003044210A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006031955A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
PL2464655T3 (pl) * 2009-08-11 2017-08-31 Biocon Limited Procesy chromatograficzne
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Glp−1アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 2型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN102703552B (zh) * 2012-05-15 2014-10-29 山东阿华生物药业有限公司 重组人胰岛素的制备方法及其产品
CN102816819B (zh) * 2012-08-13 2014-10-29 山东阿华生物药业有限公司 提高人胰岛素前体融合蛋白酶切转换成b30缺苏氨酸人胰岛素产率的方法
CN103305581B (zh) * 2013-07-04 2015-05-27 珠海联邦制药股份有限公司 一种重组人胰岛素的制备方法
MY177247A (en) * 2013-12-23 2020-09-10 Biocon Biologics Ltd Method of production of human insulin methyl ester
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
JP2018531007A (ja) * 2015-09-24 2018-10-25 ハンミ ファーマシューティカル カンパニー リミテッド インスリンの製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE50892B1 (en) * 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
JPS58501208A (ja) 1981-08-10 1983-07-28 ノルデイスク インシユリンラボラトリユ−ム インシユリン誘導体の製造法
AU551174B2 (en) 1981-09-15 1986-04-17 Nordisk Insulinlaboratorium Enzymatic preparation of human insulin or b-30 esters thereof
DK149824C (da) 1982-01-22 1987-03-16 Carlsberg Biotechnology Ltd Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyrer i insuliner
WO1983002772A1 (en) 1982-02-08 1983-08-18 Robin Ewart Offord An improved method for preparing human insulin from non-human insulin
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
CA1339955C (en) * 1986-10-14 1998-07-14 Richard Eugene Heiney Process for transforming a human insulin precursor to human insulin
ES2053723T3 (es) 1987-02-25 1994-08-01 Novo Nordisk As Nuevos derivados de insulina.
NZ273285A (en) 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
RU2141531C1 (ru) * 1999-05-26 1999-11-20 Российское акционерное общество открытого типа "Биопрепарат" Способ получения рекомбинантного инсулина человека
RU2283846C2 (ru) 1999-12-29 2006-09-20 Ново Нордиск А/С Предшественник инсулина, способ его получения и применение
JP4795599B2 (ja) 1999-12-29 2011-10-19 ノボ ノルディスク アクティーゼルスカブ 酵母において改良された発酵収率を有するインスリン前駆体及びインスリン前駆体類似体の製造方法
US6579703B2 (en) 2000-04-14 2003-06-17 University Of Maryland Biotechnology Institute Enhanced protein thermostability and temperature resistance
US20040198960A1 (en) 2001-03-29 2004-10-07 Janoff Edward N Human monoclonal antibodies against capsular polysaccharides of streptococcus pneumoniae

Also Published As

Publication number Publication date
JP2005509687A (ja) 2005-04-14
CA2464616C (en) 2012-07-24
KR100925381B1 (ko) 2009-11-09
WO2003044210A2 (en) 2003-05-30
DE60236014D1 (de) 2010-05-27
BR0213583A (pt) 2004-08-24
CN100424179C (zh) 2008-10-08
KR20050044855A (ko) 2005-05-13
RU2004118503A (ru) 2005-06-10
IL161358A0 (en) 2004-09-27
WO2003044210A3 (en) 2004-03-25
CA2464616A1 (en) 2003-05-30
RU2376379C2 (ru) 2009-12-20
PL210437B1 (pl) 2012-01-31
PL369447A1 (en) 2005-04-18
JP4404631B2 (ja) 2010-01-27
CN1589328A (zh) 2005-03-02
ES2344448T3 (es) 2010-08-27
HUP0500037A2 (hu) 2005-03-29
IL161358A (en) 2011-05-31
HU228934B1 (hu) 2013-06-28
AU2002342597A8 (en) 2003-06-10
HUP0500037A3 (en) 2010-01-28
EP1448786B1 (de) 2010-04-14
EP1448786A2 (de) 2004-08-25
AU2002342597A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
DE60236014D1 (de) Verfahren zur herstellung von insulinverbindungen
ATE461270T1 (de) Verfahren zur herstellung von l-aminosäuren
ATE493502T1 (de) Glucosamin und verfahren zur herstellung von glucosamin aus mikrobieller biomasse
ATE330014T1 (de) Verfahren zur herstellung von 1,3-propanediol durch einen rekombinanten micro-organismus in abwesenheit von coenzym b12
ATE367450T1 (de) Verfahren zur herstellung sequenzspezifischer proteasen durch gezielte evolution
ATE206407T1 (de) Verfahren zur herstellung von hiv proteasinhibitoren
ATE458066T1 (de) Verfahren zur herstellung von substituierten carbonsäureestern mittels enzymatischer hydrolyse
DE50311645D1 (de) Verfahren zur enzymatischen Herstellung enantiomerenangereicherter Beta-Aminosäuren
ATE332391T1 (de) Verfahren zur enzymatischen herstellung enantiomerenangereicherter beta-aminosäuren
DE602005024809D1 (de) Verfahren zur herstellung von gabapentin
ATE303356T1 (de) Verfahren zur herstellung von alkylendiamintriessigsäure
ATE326442T1 (de) Verfahren zur herstellung von essigsäure
ATE326545T1 (de) Verfahren zur herstellung von d- oder l-menthol
DE50208458D1 (de) Verfahren zur Herstellung von Lithiumamid
DE60015931D1 (de) Verfahren zur herstellung eines chiralen-beta-aminosäureesters
ATA2852003A (de) Verfahren zur herstellung chiraler alpha-hydroxycarbonsäuren durch enzymatische hydrolyse von chiralen cyanhydrinen
DE69528160D1 (de) Verfahren zur herstellung von 5,7 dichlor-4-hydroxychinolin
WO2004081220A3 (en) A process for enzymatically resolving an enantiomeric mixture of alpha-hydroxy acids
ATE430735T1 (de) Verfahren zur herstellung von 10,11-dihydro-10- hydroxy-5-h-dibenzäb,füazepin-5-carbonsäureamid
ATE423215T1 (de) Verfahren zur herstellung von lysosphingolipiden
DE60034699D1 (de) Verfahren zur herstellung von fumagillin
ATE321030T1 (de) Verfahren zur herstellung von phenylen-bis- benzimidazol-tetrasulfonsäure-dinatriumsalz
DE60103565D1 (de) Verfahren zur herstellung von 2-methoxy-4-methyl-6-methylamino-1,3,5-triazin
ATE317842T1 (de) Verfahren zur herstellung von 2-halo-6- nitrobenzoesäuren
ATE296895T1 (de) Verfahren zur herstellung von c4-c12-fettsäuren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties